Abstract
Renal cell carcinoma (RCC) is the most common type of primary kidney neoplasm. Though most masses are found incidentally and are asymptomatic, patients can still present with the classic triad of RCC – flank pain, hematuria, and palpable abdominal mass. Cross-sectional imaging with computed tomography (CT) or magnetic resonance imaging (MRI) is most helpful for staging and diagnosis; however, the role of renal biopsy is expanding. Many patients, especially elderly and the comorbid, can be placed on active surveillance. Focal therapy ablation is utilized in some patients; however, surgery continues to be the gold standard therapy for renal mass. Partial nephrectomy is offered to appropriately selected patients with stage I tumors, while radical nephrectomy is reserved for patients with large and/or anatomically complex renal mass. Radiation and chemotherapy play a limited role in localized RCC treatment. Targeted therapy and immunotherapy are enjoying expanding indications in the RCC space.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ljungberg B, Campbell SC, Choi HY, Cho HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–21.
Kutikov A, et al. Renal mass biopsy: always, sometimes, or never? Eur Urol. 2016;70(3):403–6.
Kim JH, Li S, Khandwala Y, Chung KJ, Park HK, Chung BI. Association of prevalence of benign pathologic findings after partial nephrectomy with preoperative imaging patterns in the United States from 2007 to 2014. JAMA Surg. 2019;154(3):225–31.
Rini BI, McKiernan JM, Chang SS, et al. Kidney. In: Amin MB, editor. AJCC cancer staging manual. 8th ed. New York: Springer; 2017. p. 739.
Ristau BT, et al. Active surveillance for small renal masses: when less is more. Eur Urol Focus. 2016;2(6):660–8.
Ginzburg S, et al. Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy. Nat Rev Urol. 2017;14:669–82.
Colombo JR Jr, Haber GP, Jelovsek JE, Lane B, Novick AC, Gill IS. Seven years after laparoscopic radical nephrectomy: oncologic and renal functional outcomes. Urology. 2008;71(6):1149.
Kim SP, et al. Collaborative review of risk benefit trade-offs between partial and radical nephrectomy in the management of anatomically complex renal masses. Eur Urol. 2017;72(1):64–75. https://doi.org/10.1016/j.eururo.2016.11.038.
Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182(3):844–53. https://doi.org/10.1016/j.juro.2009.05.035.
Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys. 1987;13(5):665.
Oudard S, etal. GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales). Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol. 2007;177(5):1698.
McDermott DF, Lee JL, Szczylik C, et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma: results from cohort A of KEYNOTE-427. J Clin Oncol. 2018;36S:ASCO #4500.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Dreyzin, E., Kutikov, A. (2021). Kidney Cancer and Its Treatment. In: Trabulsi, E.J., Lallas, C.D., Lizardi-Calvaresi, A.E. (eds) Chemotherapy and Immunotherapy in Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-52021-2_20
Download citation
DOI: https://doi.org/10.1007/978-3-030-52021-2_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-52020-5
Online ISBN: 978-3-030-52021-2
eBook Packages: MedicineMedicine (R0)